Cohen, D. J., O’Shea, J. C., Pacchiana, C. M., Levine, G., Sarembock, I., Slater, J., … ESPRIT investigators. (2002). In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin. Am J Cardiol, 89(1), 61–64. https://doi.org/10.1016/s0002-9149(01)02165-8

Cohen, David J., J Conor O’Shea, Cindy M. Pacchiana, Glenn Levine, Ian Sarembock, James Slater, Eric Conn, Jack Smith, James E. Tcheng, and ESPRIT investigators. “In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin.” Am J Cardiol 89, no. 1 (January 1, 2002): 61–64. https://doi.org/10.1016/s0002-9149(01)02165-8.

Cohen DJ, O’Shea JC, Pacchiana CM, Levine G, Sarembock I, Slater J, et al. In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin. Am J Cardiol. 2002 Jan 1;89(1):61–4.

Cohen, David J., et al. “In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin.” Am J Cardiol, vol. 89, no. 1, Jan. 2002, pp. 61–64. Pubmed, doi:10.1016/s0002-9149(01)02165-8.

Cohen DJ, O’Shea JC, Pacchiana CM, Levine G, Sarembock I, Slater J, Conn E, Smith J, Tcheng JE, ESPRIT investigators. In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin. Am J Cardiol. 2002 Jan 1;89(1):61–64.